Galderma Launches Alastin in Japan and Asia Pacific to Expand Regenerative Skincare Portfolio
Zug, Switzerland | July 20, 2026 Galderma announced the expansion of its AlastinĀ® regenerative skincare brand across the Japan...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Zug, Switzerland | July 20, 2026 Galderma announced the expansion of its AlastinĀ® regenerative skincare brand across the Japan...
New Haven, Conn., July 17, 2026 Veradermics announced the presentation of new subgroup analysis data from its Phase 2/3...
Beijing, July 16, 2026 InnoCare Pharma announced that the Phase II portion of its adaptive Phase II/III clinical trial...
FRIENDSWOOD, Texas, July 14, 2026 Castle Biosciences, Inc. has announced that its AdvanceAD-Tx⢠test has received assay approval from...
BASEL, Switzerland, June 30, 2026 Roche has announced that the U.S. Food and Drug Administration (FDA) has granted Priority...
NORTH CHICAGO, Ill., June 29, 2026 AbbVie has announced that the European Medicines Agencyās Committee for Medicinal Products for...
WESTLAKE VILLAGE, Calif., June 29, 2026 Arcutis Biotherapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has...
NORTH CHICAGO, Ill., June 26, 2026 AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved SKYRIZIĀ®...
ZUG, Switzerland, June 21, 2026 MoonLake Immunotherapeutics has announced compelling Week 52 results from its Phase 3 VELA clinical...
LONDON, United Kingdom, June 18, 2026 LabGenius Therapeutics and LG Chem have entered into a multi-year research collaboration, option,...
